N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER

N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER

The present invention relates to a N2,N4-diphenylpyrimidine-2,4-diamine derivative, a method for preparing same, and a pharmaceutical composition containing same as an active ingredient for the prevention or treatment of cancer. The derivative shows a relatively weak EGFR activity inhibitory effect...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KIM, HWAN, JEON, BYEONG UK, SHIN, INJI, PARK, CHAE WON, CHAE, CHONG HAK, DUGGIRALA, KRISHNA BABU, JUNG, MYOUNG EUN, CHOI, GILDON, CHO, BYOUNG CHUL, LEE, KWANGHO, CHOE, HYEON JEONG
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
FOODS OR FOODSTUFFS
FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT
THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to a N2,N4-diphenylpyrimidine-2,4-diamine derivative, a method for preparing same, and a pharmaceutical composition containing same as an active ingredient for the prevention or treatment of cancer. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, high inhibitory ability on EGFR mutation, and high inhibitory ability on even FLT3 or FLT3 mutation, and thus can be favorably used in the treatment of cancer with EGFR mutation or cancer with FLT3 or mutation thereof, and the derivative shows a synergy effect at the time of combinative administration, and thus can be favorably used in the treatment of combinative administration.